All Updates

All Updates

icon
Filter
Partnerships
Allarity Therapeutics and FivepHusion partner to develop personalized cancer treatment
Precision Medicine
Aug 1, 2023
This week:
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
Product updates
Uber releases five new features for holiday travel season
Travel Tech
Yesterday
Funding
Apaleo raises EUR 20 million in growth equity funding to accelerate expansion
Travel Tech
Yesterday
Partnerships
Acai Travel partners with Hopper to enhance call center operations with AI technology
Travel Tech
Yesterday
Precision Medicine

Precision Medicine

Aug 1, 2023

Allarity Therapeutics and FivepHusion partner to develop personalized cancer treatment

Partnerships

  • Clinical-stage pharmaceutical firm Allarity Therapeutics and Detsamma Investments (trading as FivepHusion) are collaborating to develop Deflexifol, a novel anti-cancer drug formulation for the treatment of solid tumors, using Allarity's drug-specific companion diagnostics (DRP) technology to potentially select patients for clinical trials.

  • The partnership aims to advance the clinical development of Deflexifol, an optimized all-in-one formulation of the chemotherapeutic agent 5-fluorouracil (5FU) and leucovorin (LV). Allarity's DRP companion diagnostics will be used to identify patients likely to respond to Deflexifol in a Phase Ib/IIa study investigating the drug, in combination with oxaliplatin and bevacizumab for unresectable metastatic colorectal cancer. 

  • The collaboration seeks to provide personalized cancer care by selecting patients who are most likely to benefit from the novel treatment. Following the study, FivepHusion will have the option to negotiate an exclusive license to use and commercialize the DRP-5FU CDx and other relevant DRP CDx in future trials and marketing efforts for Deflexifol.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.